Articles with "gefitinib induced" as a keyword



Photo from wikipedia

Gefitinib-Induced Cutaneous Toxicities in Brown Norway Rats Are Associated with Macrophage Infiltration.

Sign Up to like & get
recommendations!
Published in 2020 at "Inflammation"

DOI: 10.1007/s10753-020-01281-2

Abstract: Gefitinib (Iressa), is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used in the targeted treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Skin toxicity is the major adverse… read more here.

Keywords: gefitinib induced; gefitinib; macrophage infiltration; cutaneous toxicities ... See more keywords
Photo from wikipedia

Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity

Sign Up to like & get
recommendations!
Published in 2018 at "Anti-Cancer Drugs"

DOI: 10.1097/cad.0000000000000622

Abstract: Gefitinib is an oral tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) for non-small-cell lung cancer with EGFR mutations. Although a few studies have analyzed the causes of gefitinib-induced hepatotoxicity, research focusing on… read more here.

Keywords: gefitinib induced; induced hepatotoxicity; time; hepatotoxicity ... See more keywords
Photo from wikipedia

Gefitinib induced Pemphigus Vulgaris with PRIDE complex

Sign Up to like & get
recommendations!
Published in 2022 at "Journal of Oncology Pharmacy Practice"

DOI: 10.1177/10781552221076755

Abstract: Introduction: Pemphigus Vulgaris is a rare, noncommunicable, non-hereditary fatal autoimmune dermatological manifestation in which a painful blister initiates from the oral cavity. PRIDE complex stands for Papulopustules or paronychia, regulatory abnormality of hair and nails,… read more here.

Keywords: pemphigus vulgaris; pride complex; patient; gefitinib induced ... See more keywords

STAT6 polymorphism was correlated with gefitinib-induced diarrhea in patients with non-small cell lung cancer.

Sign Up to like & get
recommendations!
Published in 2021 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2021.39.15_suppl.e21046

Abstract: e21046 Background: Gefitinib-induced diarrhea can be severe, if not properly handled, and can result in severe dose reductions and treatment interruptions or discontinuation. However, the mechanism of gefitinib-induced diarrhea remains unclear. STAT6 promotes disruption of… read more here.

Keywords: stat6 rs167769; gefitinib; gefitinib induced; induced diarrhea ... See more keywords